Pulmonary hypertension in patients with sickle cell disease

British Journal of Haematology

Volumn 134, Issue 1, 2006, Pages 109-115

  Ataga, Kenneth I ^a   Moore, Charity G ^b   Jones, Susan ^a   Olajide, Oludamilola ^a   Strayhorn, Dell ^a   Hinderliter, Alan ^a   Orringer, Eugene P ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

Haemolysis; Mortality; Progression; Pulmonary hypertension; Sickle cell disease

Indexed keywords

ANTICOAGULANT AGENT; HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; UREA;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEMOLYSIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCREENING; SICKLE CELL ANEMIA; UREA NITROGEN BLOOD LEVEL;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD UREA NITROGEN; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FETAL HEMOGLOBIN; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; HYPERTENSION, PULMONARY; L-LACTATE DEHYDROGENASE; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK;

EID: 33744810662     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06110.x     Document Type: Article

References (32)

1. Adedeji M.O. Cespedes J. Allen K. Subramony C. Hughson M.D. 2001 Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Archives of Pathology and Laboratory Medicine, 125, 1436 1441.
2. Aslan M. Ryan T.M. Adler B. Townes T.M. Parks D.A. Thompson J.A. Tousson A. Gladwin M.T. Patel R.P. Tarpey M.M. Batinic-Haberle I. White C.R. Freeman B.A. 2001 Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proceedings of the National Academy of Science of the United States of America, 98, 15215 15220.
3. Ataga K.I. Sood N. De Gent G. Kelly E. Henderson A.G. Jones S. Strayhorn D. Lail A. Lieff S. Orringer E.P. 2004a Pulmonary hypertension in sickle cell disease. American Journal of Medicine, 117, 665 669.
4. Ataga K.I. DeCastro L.M. Swerdlow P. Saunthararajah Y. Smith W. 2004b Efficacy and safety of the Gardos channel inhibitor, ICA-17043, in patients with sickle cell anemia. Blood, 104, 103a.
5. Brun M. Bourdoulous S. Couraud P.O. Elion J. Krishnamoorthy R. Lapoumeroulie C. 2003 Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal, 3, 215 226.
6. Bunn H.F. 1997 Pathogenesis and treatment of sickle cell disease. New England Journal Medicine, 337, 762 769.
7. Castro O. Brambilla D.J. Thorington B. Reindorf C.A. Scott R.B. Gillette P. Vera J.C. Levy P.S. 1994 The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood, 84, 643 649.
8. Castro O. Hoque M. Brown B.D. 2003 Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood, 15, 1257 1261.
9. Charache S. Terrin M.L. Moore R.D. Dover G.J. Barton F.B. Erkert S.V. McMahon R.P. Bonds D.R. 1995 Multicenter study of hydroxyurea in sickle cell anemia: effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine, 332, 1317 1322.
10. Collins F.S. Orringer E.P. 1982 Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. American Journal of Medicine, 73, 814 821.
11. Gladwin M.T. Shelhamer J.H. Ognibene F.P. Pease-Fye M.E. Nichols J.S. Link B. Patel D.B. Jankowski M.A. Pannell L.K. Schechter A.N. Rodgers G.P. 2002 Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. British Journal of Haematology, 116, 436 444.
12. Gladwin M.T. Sachdev V. Jison M.L. Shizukuda Y. Plehn J.F. Minter K. Brown B. Coles W.A. Nichols J.S. Ernst I. Hunter L.A. Blackwelder W.C. Schechter A.N. Rodgers G.P. Castro O. Ognibene F.P. 2004 Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. New England Journal of Medicine, 350, 886 895.
13. Glover R.E. Ivy E.D. Orringer E.P. Maeda H. Mason R.P. 1999 Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Molecular Pharmacology, 55, 1006 1010.
14. Jison M.L. Gladwin M.T. 2003 Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. American Journal of Respiratory and Critical Care Medicine, 168, 3 4.
15. Kato G.J. Martyr S. Machado R. Sachdev V. Ernst I. Hunter L. Coles W. Nichols J. Hunter C.J. Gladwin M.T. 2004 Acute on chronic pulmonary hypertension in patients with sickle cell disease. Blood, 104, 1669a.
16. Kato G.J. Martyr S. Blackwelder W.C. Nichols J.S. Coles W.A. Hunter L.A. Brennan M.L. Hazen S.L. Gladwin M.T. 2005 Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology, 130, 943 953.
17. Machado R.F. Gladwin M.T. 2005 Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. British Journal of Haematology, 129, 449 464.
18. Machado R. Steinberg M. Bonds D. Ballas S. Blackwelder W. Barton B. Waclawiw M. Castro O. Gladwin M.T. 2005 Natriuretic peptide levels correlate with pulmonary pressures and prospective mortality in SCD: use of this biomarker to identify prevalence and mortality of pulmonary hypertension in the MSH cohort. Blood, 106, 1a.
19. Manci E.A. Culberson D.E. Yang Y.M. Gardner T.M. Powell R. Haynes Jr., J. Shah A.K. Mankad V.N. 2003 Investigators of the cooperative study of sickle cell disease. Causes of death in sickle cell disease: an autopsy study. British Journal of Haematology, 123, 359 365.
20. McKie P.M. Burnett Jr., J.C. 2005 B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clinic Proceedings, 80, 1029 1036.
21. McQuillan B.M. Picard M.H. Leavitt M. Weyman A.E. 2001 Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation, 104, 2797 2802.
22. Morris C.R. Morris S.M. Hagar W. Van Warmerdam J. Claster S. Kepka-Lenhart D. Machado L. Kuypers F.A. Vichinsky E.P. 2003 Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease American Journal of Respiratory and Critical Care Medicine, 168, 63 69.
23. Morris C.R. Kato G.J. Poljakovic M. Wang X. Blackwelder W.C. Sachdev V. Hazen S.L. Vichinsky E.P. Morris Jr., S.M. Gladwin M.T. 2005 Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Journal of the American Medical Association, 294, 81 90.
24. Oppenheimer E.H. Esterly J.R. 1971 Pulmonary changes in sickle cell disease. American Review of Respiratory Diseases, 103, 858 859.
25. Platt O.S. Thorington B.D. Brambilla D.J. Milner P.F. Rosse W.F. Vichinsky E. Kinney T.R. 1991 Pain in sickle cell disease. Rates and risk factors. New England Journal of Medicine, 325, 11 16.
26. Platt O.S. Brambilla D.J. Rosse W.F. Milner P.F. Castro O. Steinberg M.H. Klug P.P. 1994 Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639 1644.
27. Reiter C.D. Wang X. Tanus-Santos J.E. Hogg N. Cannon R.O., III. Schechter A.N. Gladwin M.T. 2002 Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nature Medicine, 8, 1383 1389.
28. Saleh A.W. Hillen H.F. Duits A.J. 1999 Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematologica, 102, 31 37.
29. Simons B.E. Santhanam V. Castaner A.J. Rao K.R. Sachdev N. Cooper R. 1988 Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adults with sickle cell anemia. Archives of Internal Medicine, 148, 1526 1528.
30. Sunshine H.R. Hofrichter J. Eaton W.A. 1979 Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins. Journal of Molecular Biology, 133, 435 467.
31. Sutton L.L. Castro O. Cross D.T. Spencer J.E. Lewis J.F. 1994 Pulmonary hypertension in sickle cell disease. American Journal of Cardiology, 74, 626 628.
32. Yung G.L. Channick R.N. Fedullo P.F. Auger W.R. Kerr K.M. Jamieson S.W. Kapelanski D.P. Moser K.M. 1998 Successful pulmonary thromboendarterectomy in two patients with sickle cell disease. American Journal of Respiratory and Critical Care Medicine, 157, 1690 1693.